Bluebird bio’s whole C-suite to leave nest for new cancer-focused spinout

Bluebird’s CEO Nick Leschly is leaving the nest to head up the gene therapy firm’s new, oncology-focused spinout — and he’s taking the rest of bluebird’s C-suite with him, the company announced Thursday.